Rituximab

Generic Name: Rituximab

Brand Names: MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo

Drug Type: Biotech

Chemical Formula: -

CAS Number: 174722-31-7

Unique Ingredient Identifier: 4F4X42SYQ6

Background: Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication: Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions: Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)

Associated Therapies: -

Clinical Trials

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Avastin
Drug: Rituximab

First Posted Date: 2004-04-27

Last Posted Date: 2012-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00081861

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: methotrexate
Drug: rituximab
Drug: placebo
Drug: corticosteroids

First Posted Date: 2003-12-15

Last Posted Date: 2013-05-09

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 465

Registration Number: NCT00074438

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Phase 2

Terminated

Conditions: Lymphoma
Leukemia
Myelodysplastic Syndrome
Myeloproliferative Disorders
Multiple Myleoma

Interventions: Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Procedure: Peripheral blood stem cell (PBSC) transplantation
Drug: Etoposide
Genetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
Drug: Doxorubicin
Procedure: Allogeneic hematopoietic stem cell transplant (HSCT)
Drug: Vincristine
Drug: Filgrastim
Drug: Prednisone
Genetic: T-Rapa cell Donor Lymphocyte Infusion (DLI)

First Posted Date: 2003-12-15

Last Posted Date: 2018-12-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 442

Registration Number: NCT00074490

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Phase 2

Terminated

Conditions: Drug/Agent Toxicity by Tissue/Organ
Brain and Central Nervous System Tumors
Lymphoma
Thrombocytopenia

Interventions: Drug: Rituxan
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Etoposide phosphate
Drug: Carboplatin
Drug: Sodium thiosulfate
Drug: Neupogen
Drug: Neulasta
Drug: Cytarabine

First Posted Date: 2003-12-11

Last Posted Date: 2023-07-06

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 17

Registration Number: NCT00074165

Locations: 🇺🇸
Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States
🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies

Phase 1

Completed

Conditions: Wegener's Granulomatosis

First Posted Date: 2003-11-05

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT00072592

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Campath-1H
Drug: Rituximab

First Posted Date: 2003-10-22

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00071396

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Lymphoma

Interventions: Drug: rituximab
Drug: methotrexate
Drug: temozolomide 100 mg/m^2
Drug: temozolomide 150 mg/m^2
Drug: temozolomide 200 mg/m^2
Radiation: radiation therapy
Drug: post-radiation therapy temozolomide

First Posted Date: 2003-09-11

Last Posted Date: 2018-02-07

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 60

Registration Number: NCT00068250

Locations: 🇺🇸
Providence Milwaukie Hospital, Milwaukie, Oregon, United States
🇺🇸
Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States
🇺🇸
Flagler Cancer Center, Saint Augustine, Florida, United States

and more 23 locations

Randomized Double Cord Blood Transplant Study

Phase 2

Completed

Conditions: Leukemia, Lymphocytic, Acute
Leukemia, Myelocytic, Acute
Leukemia, Myeloid, Chronic
Lymphoma, Non-Hodgkin

Interventions: Procedure: Expanded allogeneic cord blood (CB)
Procedure: One Unmanipulated and One Expanded Cord Blood Unit
Drug: Rituxan
Drug: Melphalan
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Radiation: Total body irradiation (TBI)

First Posted Date: 2003-08-11

Last Posted Date: 2019-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 110

Registration Number: NCT00067002

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Phase 3

Terminated

Conditions: Lymphoma, Mixed-Cell, Follicular
Lymphoma, Low-Grade
Lymphoma, Follicular
Lymphoma, Small Cleaved-Cell, Follicular

First Posted Date: 2003-05-12

Last Posted Date: 2015-01-19

Lead Sponsor: CTI BioPharma

Target Recruit Count: 800

Registration Number: NCT00060671

Locations: 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸
Sutter Health Western Division Cancer Research Group, Greenbrae, California, United States
🇺🇸
Kenmar Research Institute, Los Angeles, California, United States

and more 35 locations

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Low-Grade
Lymphoma, Small Lymphocytic
Lymphoma, Small Cleaved-Cell, Follicular
Lymphoma, Mixed-Cell, Follicular

First Posted Date: 2003-05-12

Last Posted Date: 2015-01-19

Lead Sponsor: CTI BioPharma

Target Recruit Count: 30

Registration Number: NCT00060684

Locations: 🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy